BioNTech BNTX 深 沪
等待开盘 02-02 09:30:00 美东时间
113.75
-3.020
-2.59%
华盛通- 最 高116.965
- 今 开115.96
- 成交量 89.41万股
- 最 低 113.16
- 昨 收 116.77
- 总市值 273.00亿
- 52周最高 124.4873
- 市盈率 静 --
- 换手率 0.37%
- 52周最低 81.20
- 委 比 -1.05%
- 总股本 2.40亿
- 历史最高 462.4502
- 量 比 1.01
- 振 幅 3.26%
- 历史最低 10.9752
- 每 手 1
- 风险率 7.92%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pediatrics group defies CDC, endorses COVID, flu shots for children
The American Academy of Pediatrics updated immunization schedule for children and adolescents recommends the COVID-19 and flu vaccines, in contradiction to CDC guidelines. In January, the agency forma...
01-26 23:55
FOCUS-Vaccine makers feel a chill as US Health Secretary Kennedy's rhetoric becomes reality
FOCUS-Vaccine makers feel a chill as US Health Secretary Kennedy's rhetoric becomes reality Kennedy's vaccine policy shifts spark industry frustration Experts link drop in vaccination rates to US rhetoric Vaccine-focused biotech firms face valuation pressure By Bhanvi Satija LONDON, Jan 22 (Reuters)
01-22 14:00
FDA Grants Fast Track Designation to BioNTech's BNT113 for HPV16+ Head and Neck Cancer
FDA Grants Fast Track Designation to BioNTech's BNT113 for HPV16+ Head and Neck Cancer BioNTech SE announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BNT113, an investigational mRNA cancer immunotherapy. BNT113 is being developed for the treatment of pat
01-21 20:05
JPM2026：中国企业的迭代创新
（来源：Armstrong生物药资讯） ▎Armstrong 2026年JPM大会已经落幕，中国药企和生物技术公司成为大会关注的焦点之一，艾伯维引进荣昌生物P...
01-20 19:31
美股大行评级 | 潜在上涨空间31.6%！巴克莱上调台积电目标价至450美元；第一地平线全国银行获5家机构上调目标价
今日重点评级关注：Guggenheim：维持MBX Biosciences"买入"评级，目标价从77美元升至88美元；摩根士丹利：维持DraftKings"超配"评级，目标价从50美元升至53美元
01-20 10:26
Goldman Sachs Upgrades BioNTech to Buy, Raises Price Target to $142
Goldman Sachs analyst Asad Haider upgrades BioNTech (NASDAQ:BNTX) from Neutral to Buy and raises the price target from $115 to $142.
01-16 19:56
JPM Day 2｜阿斯利康/礼来/诺和诺德等巨头战略前瞻：37个项目、550亿投入与104项III期研究（PPT下载）
（来源：求实药社） 2026年摩根大通医疗健康大会（JPM26）进入第二天，医药圈的焦点来到细分领域。 减肥药赛道双雄砸钱竞速，曾经的新冠疫苗顶流跨界转型，仿制...
01-15 12:06
BioNTech eyes catalyst-rich 2026 as it advances multi-product oncology strategy
BioNTech SE (BNTX) said Monday it will continue executing its strategy in 2026 to evolve into a multi-product oncology company, with the year expected to be catalyst-rich as late-stage programs advanc...
01-12 20:01
